Immunogenic cell death induced by ginsenoside Rg3: Significance in dendritic cell-based anti-tumor immunotherapy

Immune Network

Volumn 16, Issue 1, 2016, Pages 75-84

  Son, Keum Joo ^a   Choi, Ki Ryung ^a   Lee, Seog Jae ^b   Lee, Hyunah ^a  

^a Pharmicell Co Ltd   (South Korea)

^b Jeju National University School of Medicine   (South Korea)

Author keywords

CRT; DC; Ginsenoside Rg3; HSPs; Immunogenic cell death

Indexed keywords

CALRETICULIN; CHAPERONIN 60; DOXORUBICIN; GAMMA INTERFERON; GINSENOSIDE RG 3; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B16-F10 CELL LINE; CANCER IMMUNOTHERAPY; CELL DEATH; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DENDRITIC CELL; FEMALE; IMMUNOGENICITY; INTERFERON PRODUCTION; MOUSE; NONHUMAN; PERCENTAGE OF APOPTOTIC CELLS; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

EID: 84974659433     PISSN: 15982629     EISSN: 20926685     Source Type: Journal    
DOI: 10.4110/in.2016.16.1.75     Document Type: Article

References (21)

1. Kim, J. W., S. Y. Jung, Y. H. Kwon, J. H. Lee, Y. M. Lee, B. Y. Lee, and S. M. Kwon. 2012. Ginsenoside Rg3 attenuates tumor angiogenesis via inhibiting bioactivities of endothelial progenitor cells. Cancer Biol. Ther. 13: 504-515.
2. Nam, K. Y., J. E. Choi, S. C. Hong, K. M. Pyo, and J. D. Park. 2014. Recent Progress in Research on Anticancer Activities of Ginsenoside-Rg3. Kor. J. Pharm. 45: 1-10.
3. Cirone, M., R. L. Di, L. V. Lotti, V. Conte, P. Trivedi, R. Santarelli, R. Gonnella, L. Frati, and A. Faggioni. 2012. Activation of dendritic cells by tumor cell death. Oncoimmunology 1: 1218-1219.
4. Fucikova, J., P. Kralikova, A. Fialova, T. Brtnicky, L. Rob, J. Bartunkova, and R. Spisek. 2011. Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res. 71: 4821-4833.
5. Zitvogel, L., O. Kepp, L. Senovilla, L. Menger, N. Chaput, and G. Kroemer. 2010. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin. Cancer Res. 16: 3100-3104.
6. Panaretakis, T., O. Kepp, U. Brockmeier, A. Tesniere, A. C. Bjorklund, D. C. Chapman, M. Durchschlag, N. Joza, G. Pierron, E. P. van, J. Yuan, L. Zitvogel, F. Madeo, D. B. Williams, and G. Kroemer. 2009. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J. 28: 578-590.
7. Obeid, M., A. Tesniere, F. Ghiringhelli, G. M. Fimia, L. Apetoh, J. L. Perfettini, M. Castedo, G. Mignot, T. Panaretakis, N. Casares, D. Metivier, N. Larochette, E. P. van, F. Ciccosanti, M. Piacentini, L. Zitvogel, and G. Kroemer. 2007. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13: 54-61.
8. Cragg, G. M., D. J. Newman, and K. M. Snader. 1997. Natural products in drug discovery and development. J. Nat. Prod. 60: 52-60.
9. Joo, E. J., Y. W. Ha, H. Shin, S. H. Son, and Y. S. Kim. 2009. Generation and characterization of monoclonal antibody to ginsenoside rg3. Biol. Pharm. Bull. 32: 548-552.
10. Gao, J. L., G. Y. Lv, B. C. He, B. Q. Zhang, H. Zhang, N. Wang, C. Z. Wang, W. Du, C. S. Yuan, and T. C. He. 2013. Ginseng saponin metabolite 20(S)-protopanaxadiol inhibits tumor growth by targeting multiple cancer signaling pathways. Oncol. Rep. 30: 292-298.
11. Wang, C. Z., H. H. Aung, M. Ni, J. A. Wu, R. Tong, S. Wicks, T. C. He, and C. S. Yuan. 2007. Red American ginseng: ginsenoside constituents and antiproliferative activities of heat-processed Panax quinquefolius roots. Planta Med. 73: 669-674.
12. Liu, T. G., Y. Huang, D. D. Cui, X. B. Huang, S. H. Mao, L. L. Ji, H. B. Song, and C. Yi. 2009. Inhibitory effect of ginsenoside Rg3 combined with gemcitabine on angiogenesis and growth of lung cancer in mice. BMC Cancer 9: 250.
13. Zhang, Q., X. Kang, and W. Zhao. 2006. Antiangiogenic effect of low-dose cyclophosphamide combined with ginsenoside Rg3 on Lewis lung carcinoma. Biochem. Biophys. Res. Commun. 342: 824-828.
14. Yi, C., X. B. Huang, and M. Hou. 2005. [Experimental study on effect of chemotherapy combined ginsengnoside Rg3 in treating pulmonary carcinoma]. Zhongguo Zhong. Xi. Yi. Jie. He. Za Zhi. 25: 58-59.
15. Hu, S. S., L. K. Zhou, Y. Ba, H. I. Li, and C. H. Zhu. 2011. A meta-analysis of Ginsenoside Rg3 for non- small cell lung cancer. Clin. Oncol. Cancer Res. 8: 175-180.
16. Liu, J. W., J. X. Chen, L. H. Yu, Y. X. Tian, X. Y. Cui, Q. Yan, and L. Fu. 2004. [Inhibitory effect of ginsenoside-Rg3 on lung metastasis of mouse melanoma transfected with ribonuclease inhibitor]. Zhonghua Zhong. Liu Za Zhi. 26: 722-725.
17. Xu, T. M., M. H. Cui, Y. Xin, L. P. Gu, X. Jiang, M. M. Su, D. D. Wang, and W. J. Wang. 2008. Inhibitory effect of ginsenoside Rg3 on ovarian cancer metastasis. Chin. Med. J. (Engl.) 121: 1394-1397.
18. Kim, Y. J., W. I. Choi, B. N. Jeon, K. C. Choi, K. Kim, T. J. Kim, J. Ham, H. J. Jang, K. S. Kang, and H. Ko. 2014. Stereospecific effects of ginsenoside 20-Rg3 inhibits TGF-beta1-induced epithelial-mesenchymal transition and suppresses lung cancer migration, invasion and anoikis resistance. Toxicology 322: 23-33.
19. Lee, S. G., B. S. Kim, and J. O. Nam. 2014. Ginsenoside Rg3 induces apoptosis in B16F10 melonoma cells. J. Life Sci. 24: 1001-1005.
20. Oh, S. J., C. K. Ryu, S. Y. Baek, and H. Lee. 2011. Cellular mechanism of newly synthesized indoledione derivative-induced immunological death of tumor cell. Immune Netw. 11: 383-389.
21. Park, D., D. K. Bae, J. H. Jeon, J. Lee, N. Oh, G. Yang, Y. H. Yang, T. K. Kim, J. Song, S. H. Lee, B. S. Song, T. H. Jeon, S. J. Kang, S. S. Joo, S. U. Kim, and Y. B. Kim. 2011. Immunopotentiation and antitumor effects of a ginsenoside Rg(3)-fortified red ginseng preparation in mice bearing H460 lung cancer cells. Environ. Toxicol. Pharmacol. 31: 397-405.